ClinicalTrials.gg
CompletedNCT01405911Updated Jan 18, 2020Results posted

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

A Phase 2 interventional study of Placebo for Sitagliptin 25 mg and Placebo for Sitagliptin 50 mg in Glucose Intolerance, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using diet and exercise therapy.

02

Conditions studied

  • Glucose Intolerance

Browse trials for

03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's enrollment of 242 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Impaired glucose tolerance
  • On diet/exercise therapy
  • Unlikely to conceive
  • Meets all of the following glycemic parameters: (Japan Diabetes Society value) \<6.1%, Fasting Plasma Glucose \<126 mg/dL, and 2-hr plasma glucose level in 75g oral glucose tolerance test ≥140 mg/dL and \<200 mg/dL

Exclusion criteria

Exclusion Criteria:

  • History of diabetes mellitus
  • Disease or condition of clear or likely glucose tolerance disorder
  • Previously treated with a drug to prevent diabetes and/or any antihyperglycemic drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
242 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.

    Drug: Placebo for Sitagliptin 25 mg · Drug: Placebo for Sitagliptin 50 mg

  • Experimental
    Sitagliptin 25 mg

    Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.

    Drug: Placebo for Sitagliptin 50 mg · Drug: Sitagliptin 25 mg

  • Experimental
    Sitagliptin 50 mg

    Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.

    Drug: Placebo for Sitagliptin 25 mg · Drug: Sitagliptin 50 mg

Interventions

  • DrugPlacebo for Sitagliptin 25 mg

    1 tablet orally once daily before breakfast for 8 weeks

  • DrugPlacebo for Sitagliptin 50 mg

    1 tablet orally once daily before breakfast for 8 weeks

  • 1 tablet orally once daily before breakfast for 8 weeks

    Also known as: MK-0431/ONO-5435

  • 1 tablet orally once daily before breakfast for 8 weeks

    Also known as: MK-0431/ONO-5435

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8

    Glucose total AUC 0-2 hours for MTT was measured at Baseline (Week 0) and at Week 8. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 8, participants received study drug or placebo 30 minutes prior to consuming a standard meal.

    Time frame: Baseline (Week 0) and Week 8

  2. Percentage of Participants Who Experienced One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 10 weeks

  3. Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7

    Glucose total AUC 0-2 hours for 75 g OGTT was measured at Baseline (Week -1) and at Week 7. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at 75 g glucose loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 7, participants received study drug or placebo 30 minutes prior to loading 75 g glucose solution.

    Time frame: Baseline (Week -1) and Week 7

07

Results

Posted Dec 26, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboSitagliptin 25 mgSitagliptin 50 mg
Started838277
Treated828277
Completed797976
Not completed431
Withdrew: Pre-treatment lab ae010
Withdrew: Lost to follow-up010
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject311

Outcome measures

PrimaryPercent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8

Glucose total AUC 0-2 hours for MTT was measured at Baseline (Week 0) and at Week 8. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 8, participants received study drug or placebo 30 minutes prior to consuming a standard meal.

Time frame:
Baseline (Week 0) and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8
Percent changePlaceboSitagliptin 25 mgSitagliptin 50 mg
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8-2.42 (-4.48 to -0.31)-9.52 (-11.43 to -7.57)-11.49 (-13.40 to -9.55)
Statistical analysis
  • Placebo vs Sitagliptin 25 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -7.11 · 95% CI -9.85 to -4.36
  • Placebo vs Sitagliptin 50 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -9.08 · 95% CI -11.82 to -6.33
  • Sitagliptin 25 mg vs Sitagliptin 50 mg · Constrained Longitudinal Data Analysis · p = 0.143 · Difference in least squares means: -1.97 · 95% CI -4.61 to 0.67
SecondaryPercent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7

Glucose total AUC 0-2 hours for 75 g OGTT was measured at Baseline (Week -1) and at Week 7. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at 75 g glucose loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 7, participants received study drug or placebo 30 minutes prior to loading 75 g glucose solution.

Time frame:
Baseline (Week -1) and Week 7
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7
Percent changePlaceboSitagliptin 25 mgSitagliptin 50 mg
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7-3.68 (-6.66 to -0.60)-21.38 (-23.81 to -18.87)-20.09 (-22.61 to -17.48)
Statistical analysis
  • Placebo vs Sitagliptin 25 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -17.70 · 95% CI -21.55 to -13.86
  • Placebo vs Sitagliptin 50 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -16.41 · 95% CI -20.32 to -12.50
  • Sitagliptin 25 mg vs Sitagliptin 50 mg · Constrained Longitudinal Data Analysis · p = 0.469 · Difference in least squares means: 1.30 · 95% CI -2.22 to 4.82
PrimaryPercentage of Participants Who Experienced One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 10 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
Percentage of participantsPlaceboSitagliptin 25 mgSitagliptin 50 mg
Percentage of Participants Who Experienced One or More Adverse Events (AEs)30.934.141.0
PrimaryPercentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 8 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)
Percentage of participantsPlaceboSitagliptin 25 mgSitagliptin 50 mg
Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)0.00.00.0

Adverse events

Collected over Up to 10 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/81 (0%)0/81 (0%)13/81 (16%)
Sitagliptin 25 mg0/82 (0%)0/82 (0%)14/82 (17.1%)
Sitagliptin 50 mg0/78 (0%)0/78 (0%)11/78 (14.1%)
Most frequent other events
Most frequent other events
EventPlaceboSitagliptin 25 mgSitagliptin 50 mg
NasopharyngitisInfections and infestations7/819/827/78
HypoglycaemiaMetabolism and nutrition disorders7/815/824/78

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboSitagliptin 25 mgSitagliptin 50 mgTotal
Mean61.9 ± 10.663.1 ± 9.561.9 ± 9.362.3 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSitagliptin 25 mgSitagliptin 50 mgTotal
Female353832105
Male484445137
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab. 2015 Nov;17(11):1033-41. doi: 10.1111/dom.12507. Epub 2015 Jul 17. PubMed 26094974 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Apr 2012, 7 months.

Results were first posted in Dec 2019, 7 years 8 months after primary completion.

Of 22 phase 2 interventional studies under Glucose Intolerance, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 99. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2011
First posted
Jul 29, 2011
StartActual
Aug 16, 2011
Primary completionActual
Apr 9, 2012
CompletionActual
Apr 9, 2012
Results first posted
Dec 26, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01405911
Responsible party
Sponsor
First posted
Jul 29, 2011
Start date
Aug 16, 2011
Primary completion
Apr 9, 2012
Completion
Apr 9, 2012
Results posted
Dec 26, 2019
Last update
Jan 18, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion